

Figure S1. Sensitivity analysis for HLA-DQA1*02:01 and TKI-induced liver injury




Figure S2. Sensitivity analysis for HLA-DQB1*02:02 and TKI-induced liver injury




Figure S3. Sensitivity analysis for HLA-DRB1*07:01 and TKI-induced liver injury

Table S1 Search terms

#	Search term
1	“Human leukocyte antigen” OR “human leukocyte antigens” OR HLA “afatinib” OR “alectinib” OR “axitinib” OR “bosutinib” OR “brigatinib” OR “cabozantinib” OR “ceritinib” OR “cobimetinib” OR “crizotinib” OR “dabrafenib” OR “dasatinib” OR “erlotinib” OR “everolimus” OR “gefitinib” OR “ibrutinib” OR “imatinib” OR “lapatinib” OR “lenvatinib” OR “neratinib”
2	OR “nilotinib” OR “nintendanib” OR “osimertinib” OR “palbociclib” OR “pazopanib” OR “ponatinib” OR “regorafenib” OR “ribociclib” OR “ruxolitinib” OR “sirolimus” OR “sorafenib” OR “sunitinib” OR “temsirrolimus” OR “tofacitinib” OR “trametinib” OR “vandetanib” OR “vemurafenib” OR “tyrosine kinase inhibitor” OR “TKI”
3	ADR or "adverse drug reaction" or "adverse drug reactions" or "adverse event" or "adverse events"
4	"Drug effect" or "drug effects" or "drug toxicity"
5	“liver injury” OR “liver toxicity” OR “hepatotoxicity”
6	#1 and #2 and (#3 or #4 or #5)
